1. Clinical Gastroenterology and Hepatology
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis 
David M. Faleck, Adam Winters, Shreya Chablaney, Preeti Shashi, Joseph Meserve, Aaron Weiss, Satimai Aniwan, Jenna L. Koliani- Pace, Gursimran Kochhar, Brigid Boland, Siddharth Singh, Robert Hirten, Eugenia Shmidt, Varun Kesar, Karen Lasch, Michelle Luo, Matthew Bohm, Sashidhar Varma, Monika Fischer, David Hudesman, Shannon Chang, Dana Lukin, Keith Sultan, Arun Swaminath, Nitin Gupta, Corey A. Siegel, Bo Shen, William J. Sandborn, Sunanda Kane, Edward V. Loftus, Bruce E. Sands, Jean-Frederic Colombel, Parambir S. Dulai, Ryan Ungaro 
Clinical Gastroenterology and Hepatology 
DOI: /j.cgh
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
Cumulative rates of remission stratified by disease duration ≤2 years or >2 years. (A) Clinical remission. (B) Corticosteroid-free remission. (C) Endoscopic remission.
Clinical Gastroenterology and Hepatology DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

3. Supplementary Figure 1
Cumulative rates of remission stratified by disease duration ≤2 years, >2 to ≤5 years, >5 years. (A) Clinical remission (P = .01 for ≤2 vs >5 years; P > .10 for all other comparisons). (B) Corticosteroid-free remission (P < .01 for ≤2 vs >5 years and P = .02 for ≤2 vs >2 to ≤5 years; P > .10 for all other comparisons). (C) Endoscopic remission (P = .02 for ≤2 vs >5 years and P = .05 for ≤2 vs >2 to ≤5 years; P > .10 for all other comparisons).
Clinical Gastroenterology and Hepatology DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions